Alpha Emitter Market Size to Exceed USD 3,216.3 Mn by 2032

The Alpha Emitter Market, estimated at USD 1,619.3 Mn in 2025, is expected to exhibit a CAGR of 10.3% and reach USD 3,216.3 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Increasing regulatory body approvals for the alpha radiation cancer therapy to the key market players is expected to drive the market growth in the region over the forecast period. For instance, in October 2021, the U.S. Food and Drug Administration (FDA) granted breakthrough device designation to Alpha Tau’s alpha radiation cancer therapy for treating patients that are suffering from recurrent glioblastoma multiforme (GBM). Alpha Tau Medical is an Israel-based medical device company that develops and markets diffusing alpha emitter radiation therapy ('Alpha DaRT') for treating solid tumors. Alpha diffusing alpha emitter radiation therapy (DaRT) works with the insertion of radium-224 impregnated sources intratumorally, and thus, enables conformal alpha irradiation of solid tumors. Short lived daughters, which are released from the impregnated source with the decay of radium, scatter while emitting high-energy alpha particles, and subsequently kill the tumor. Alpha DaRT can be used in treatment of recurrent GBM as an adjunct to standard medical treatments or as a standalone therapy, when no other standard medical therapies worked.

Global Alpha Emitter Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdowns in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

Post COVID-19 pandemic, many regulatory authorities released stringent guidelines for the initiation of clinical trials including the trials for global alpha emitter market.  Market players initiated clinical trials post COVID-19 pandemic for the development of new targeted alpha therapy for treatment of various cancer such as skin cancer, breast cancer, prostate cancer, and others. Furthermore, in January 2022, Alpha Tau Medical, a radiopharmaceutical company, announced the positive results for its clinical trial of Alpha DaRT for treatment of the soft tissue and malignant skin cancers. Alpha Tau Medical announced that the diffusing alpha emitter radiation therapy named Alpha DaRT successfully generated complete responses (CRs) as per RECIST v1.1 criteria in 10 patients with malignant skin and soft tissue cancers who were enrolled to an ongoing single-institution pilot feasibility trial (NCT04377360), and the trial met its primary-end feasibility end point as all patients enrolled to the trial had successfully received the radiation treatment.

Global Alpha Emitter Market: Key Developments

In November 2022, NMR,  a commercial-stage nuclear medicine company focused on advancing patient care by providing diagnostic and therapeutic radioisotopes, novel radiopharmaceuticals and customized radiopharmaceutical development services, announced expansion of its business platform with the formation of a new Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit in Beloit, U.S. The CDMO will provide collaborator companies with a full range of customized radiopharmaceutical development and commercialization services, and serve NMR in progressing its own radiopharmaceutical programs.

In July 2021, Orano Med, a subsidiary of the Orano group announced inauguration of the Maurice Tubiana Laboratory and its new Research & Development Center in Bessines-surGartempe (France) dedicated to the manufacturing of Lead212 (212Pb), a rare radioisotope used for the development of Targeted Alpha Therapies, an innovative approach against cancers with limited therapeutic options.

In May 2022, IONETIX Corporation and Atonco, a radiopharmaceutical company, announced that they had entered into a partnership to fight bladder cancer. Through this agreement, IONETIX Corporation will produce astatine-211 and manufacture patient doses for clinical use, according to CGMP regulations. The partnership includes the supply of the radioisotope, astatine-211, the GMP manufacturing of the injectable doses and specifies the terms of the U.S. FDA agent agreement signed in August 2021.

In June 2022, Fusion Pharmaceuticals Inc., a clinical-stage oncology company, and NIOWAVE Inc., announced that the companies had entered into a collaboration and supply agreement for the development, production, and supply of actinium-225. In accordance with the agreement, Fusion Pharmaceuticals Inc. will invest up to US$ 5 million in NIOWAVE Inc. to advance their technology and increase current actinium-225 production capacity. In exchange, Fusion Pharmaceuticals Inc. will be granted guaranteed access to a predetermined portion of Niowave's capacity for the resulting actinium-225 as well as priority access to any surplus supply produced. In accordance with the terms of the agreement, Fusion Pharmaceuticals Inc. will also have the option to invest in actinium-225 production that is scaled to meet Fusion's demands in the future.

Browse 35 Market Data Tables and 45 Figures spread through 244 Pages and in-depth TOC on “Global Alpha Emitter Market”- Forecast to 2030, by Type of Radionuclide (Radium (Ra-223), Actinium (Ac-225), Lead (Pb-212), Astatine-211, Bismuth-213 and Others), by Source (Natural Sources (Uranium-238 and Radium-226) Artificially Produced Sources (Plutonium, Americium, Curium and Californium), by Application (Bone Metastases, Prostate Cancer, Neuroendocrine Tumors, Ovarian Cancer and Others), by End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/alpha-emitter-market-5534

Key Takeaways of the Global Alpha Emitter Market:

• The global alpha emitter is expected to exhibit a CAGR of 10.3% during the forecast period due to an increase in adoption of inorganic growth strategies such as collaboration by key market players. For instance, on January 5, 2022, Actinium Pharmaceuticals, Inc. and EpicentRx, Inc., a clinical cancer immunotherapy company collaborated, in order to research about the Actinium pharmaceutical inc. product that is Actimab-A targeted radiotherapy in combination with RRx-001.
• Among application, bone metastases segment is estimated to hold a dominant position in the global alpha emitter over the forecast period, owing to increasing research and development in targeted alpha-particle emitting radiopharmaceuticals as therapy for prostate cancer patients with bone metastases. For instance, according to an article published in April 2021, by the National Center for Biotechnology Information, researchers form Wake Forest University Health Sciences, North Carolina, U.S., and the University of Iowa, U.S., reported that radium-223 dichloride, an alpha-particle-emitting radiopharmaceutical, improves the overall survival of prostate cancer patients with bone metastases.
• Major players operating in the global alpha emitter market include Actinium Pharmaceutical Inc., Alpha Tau Medical Ltd, Bayer AG, Bracco, Cardinal Health, Eckert & Ziegle, Fusion Pharmaceuticals, IBA Worldwide, NorthStar Medical Radioisotopes (NMR), Orano Group, Viewpoint Molecular Targeting, RadioMedix, Telix Pharmaceuticals Limited., TerraPower, LLC, NIOWAVE Inc. and IONETIX Corporation.